Equities
Health CareMedical Equipment and Services
  • Price (USD)363.64
  • Today's Change2.28 / 0.63%
  • Shares traded280.24k
  • 1 Year change+23.81%
  • Beta0.9184
Data delayed at least 15 minutes, as of Sep 19 2024 16:53 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy9
Outperform13
Hold10
Sell0
Strong Sell0

Share price forecast in USD

The 27 analysts offering 12 month price targets for Stryker Corp have a median target of 378.00, with a high estimate of 410.00 and a low estimate of 309.86. The median estimate represents a 4.60% increase from the last price of 361.36.
High13.5%410.00
Med4.6%378.00
Low-14.3%309.86

Dividends in USD

In 2023, Stryker Corp reported a dividend of 3.05 USD, which represents a 7.58% increase over last year. The 9 analysts covering the company expect dividends of 3.17 USD for the upcoming fiscal year, an increase of 4.03%.
Div growth (TTM)7.58%
More ▼

Earnings history & estimates in USD

On Jul 30, 2024, Stryker Corp reported 2nd quarter 2024 earnings of 2.81 per share. This result was in line with the consensus of the 26 analysts following the company and exceeded last year's 2nd quarter results by 10.63%.
The next earnings announcement is expected on Oct 31, 2024.
Average growth rate+5.54%
Stryker Corp reported annual 2023 earnings of 10.60 per share on Jan 30, 2024.
Average growth rate+7.13%
More ▼

Revenue history & estimates in USD

Stryker Corporation had 2nd quarter 2024 revenues of 5.42bn. This bettered the 5.41bn consensus of the 24 analysts covering the company. This was 13.48% above the prior year's 2nd quarter results.
Average growth rate+2.57%
Stryker Corporation had revenues for the full year 2023 of 20.50bn. This was 11.11% above the prior year's results.
Average growth rate+8.64%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.